PRESS RELEASE published on 04/17/2026 at 21:00, 5 months 8 days ago Informations privilégiées / Autres communiqués Innate Pharma présentera des résultats intermédiaires de l'essai de Phase 2 MATISSE évaluant IPH5201 lors d'une session plénière dédiée aux essais cliniques au congrès de l'AACR 2026 Essai Clinique Cancer Du Poumon Innate Pharma AACR 2026 IPH5201
BRIEF published on 04/13/2026 at 07:05, 5 months 13 days ago Innate Pharma Updates Share and Voting Rights as of April 2026 Biotechnology Shares And Voting Rights Innate Pharma April 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 5 months 13 days ago Innate Pharma : Mise à Jour du Capital et des Droits de Vote Droits De Vote Biotechnologie Actions Immunothérapie Innate Pharma
BRIEF published on 04/13/2026 at 07:05, 5 months 13 days ago Innate Pharma met à jour ses actions et ses droits de vote à compter d'avril 2026 Biotechnologie Innate Pharma Actions Et Droits De Vote Avril 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 5 months 13 days ago Innate Pharma: Capital and Voting Rights Update Voting Rights Biotechnology Actions Immunotherapy Innate Pharma
PRESS RELEASE published on 04/13/2026 at 07:00, 5 months 13 days ago Inside Information / Other news releases Innate Pharma to hold its Annual General Meeting of shareholders on May 21, 2026 at 10:30 a.m. CEST in Marseille. Shareholders must register shares by May 14, 2026, 00:00 Paris time, to attend Annual General Meeting Shareholders Registration Innate Pharma Marseille
PRESS RELEASE published on 04/13/2026 at 07:00, 5 months 13 days ago Inside Information / Other news releases Innate Pharma releases total shares and voting rights as of April 9, 2026, in compliance with French regulations. Learn about its innovative immunotherapies for cancer patients Voting Rights Shares French Regulations Innate Pharma Immunothérapies
PRESS RELEASE published on 04/13/2026 at 07:00, 5 months 13 days ago Informations privilégiées / Autres communiqués Innate Pharma a publié le nouveau nombre d'actions et de droits de vote au 9 avril 2026 conformément aux règlements de l'AMF. Découvrez les détails dans le communiqué de presse Droits De Vote Actions AMF Communiqué De Presse Innate Pharma
BRIEF published on 04/03/2026 at 07:05, 5 months 23 days ago Innate Pharma participera à la Kempen Life Sciences Conference Conference Innate Pharma Biotechnologies Immunothérapies Kempen Life Sciences
BRIEF published on 04/03/2026 at 07:05, 5 months 23 days ago Innate Pharma participera à la conférence Kempen Life Sciences Biotechnologie Innate Pharma Réunions Avec Les Investisseurs Conférence De Kempen Immunothérapies Contre Le Cancer
Published on 09/26/2026 at 01:00, 13 hours 48 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 13 hours 48 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 16 hours 33 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 21 hours 18 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 23 hours 48 minutes ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 07:45, 7 hours 2 minutes ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 14 hours 46 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 20 hours 17 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 18:00, 20 hours 47 minutes ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26
Published on 09/25/2026 at 17:45, 21 hours 3 minutes ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 21 hours 8 minutes ago Availability of the 2026 half-year financial report
